递表 |「泰励生物-B」递表港交所，核心产品TSN1611尚处临床二期

Core Viewpoint - Tyligand Biosciences is a clinical-stage biopharmaceutical company focused on developing innovative cancer therapies, planning to list on the Hong Kong Stock Exchange under the 18A rule with a primary focus on small molecule drugs and ADC candidates [1][3]. Financial Performance - The company reported revenues of approximately RMB 0.08 billion for 2024 and RMB 0.11 billion for the first nine months of 2025, reflecting a year-on-year increase of 654.18% [4]. - The net losses were RMB 0.70 billion in 2024 and RMB 1.23 billion in the first nine months of 2025, with a year-on-year increase of 335.23% [4]. - Gross margins were reported at 90.64% for 2024 and 78.31% for the first nine months of 2025 [4]. - Research and development expenses were RMB -0.73 billion for 2024 and RMB -0.91 billion for the first nine months of 2025, with a year-on-year increase of 80.62% [4]. Drug Development Pipeline - The company has a drug portfolio that includes four candidates, with TSN1611 being the core product currently in Phase 2 clinical trials in the US and China for non-small cell lung cancer (NSCLC) [1][3]. - TSN1611 is a highly selective oral KRAS G12D inhibitor, with plans for a pivotal registration trial in China [1]. Industry Overview - The global market for KRAS G12D inhibitors is projected to grow from USD 81.8 million in 2027 to USD 3,481.6 million by 2035, with a compound annual growth rate (CAGR) of 59.8% [8]. - The Chinese market for KRAS G12D inhibitors is expected to increase from USD 12.3 million in 2027 to USD 446.5 million by 2035, with a CAGR of 56.7% [8][9]. Competitor Analysis - Comparable companies in the industry include Jinfang Pharmaceutical-B, Hengrui Medicine, and Revolution Medicines, with varying IPO details and financial metrics [12]. - Tyligand Biosciences has a current gross margin of 90.64%, which is competitive within the industry [12]. Management and Shareholding Structure - The board of directors consists of five members, including two executive directors and three non-executive directors [13]. - Major shareholders include Tyligand Holdings, which holds 23.66% of the company, with significant stakes from other investors such as Tencent and Kangzhe Pharmaceutical [15]. Financing History - The company has undergone multiple rounds of financing, with the latest B round valuing the company at approximately USD 222.2 million [17].